none8noObjective: The optimal choice of a second biological disease-modifying anti-rheumatic drug (bDMARD) after failure with first line tumour necrosis factor inhibitor (TNFi) represents a critical therapeutic challenge. This study aims to evaluate the persistence with treatment using second line bDMARDs with different mechanisms of action in rheumatoid arthritis (RA) patients with inadequate response to first line TNFi. Method: A retrospective cohort study on administrative healthcare databases was conducted. We analysed the relationship between different bDMARDs and persistence with treatment in RA patients who started second line bDMARD therapy according to two different strategies: cycling (second TNFi) or switching [change in mechanis...
Objective: To establish evidence-based and experts' opinion filtered statements on the optimal treat...
Objective. To evaluate 4-year retention rates of tumor necrosis factor-α (TNF-α) inhibitors adalimum...
Objective. To evaluate 4-year retention rates of tumor necrosis factor-α (TNF-α) inhibitors adalimum...
Objective: The optimal choice of a second biological disease-modifying anti-rheumatic drug (bDMARD) ...
Objectives EULAR recommendations do not suggest which biologic disease-modifying anti-rheumatic drug...
The introduction of biologic disease\u2013modifying anti-rheumatic drugs (bDMARDs) has dramatically ...
Machaon MK Bonafede,1 Jeffrey R Curtis,2 Donna McMorrow,1 Puneet Mahajan,3 Chieh-I Chen4 1Outcomes R...
Background Switching to a second tumour necrosis factor inhibitor (TNFi) after discontinuation of a ...
According to international recommendations, the selection of the biologic disease modifying anti-rhe...
Aim: To describe the persistence of biologic disease modifying anti-rheumatic drugs (bDMARDs) in Aus...
OBJECTIVE: To evaluate 4-year retention rates of tumor necrosis factor-α (TNF-α) inhibitors adalimum...
Introduction/Objective: The efficacy of biologic therapy in the treatment of rheumatoid arthritis (R...
New biologic agents have changed the paradigm of rheumatoid arthritis treatment, leading to improvem...
The aim was to describe the real-world treatment persistence of subcutaneous TNF inhibitors (TNFi) f...
Background: Rheumatoid arthritis (RA), the most common autoimmune disease in the UK, is a chronic sy...
Objective: To establish evidence-based and experts' opinion filtered statements on the optimal treat...
Objective. To evaluate 4-year retention rates of tumor necrosis factor-α (TNF-α) inhibitors adalimum...
Objective. To evaluate 4-year retention rates of tumor necrosis factor-α (TNF-α) inhibitors adalimum...
Objective: The optimal choice of a second biological disease-modifying anti-rheumatic drug (bDMARD) ...
Objectives EULAR recommendations do not suggest which biologic disease-modifying anti-rheumatic drug...
The introduction of biologic disease\u2013modifying anti-rheumatic drugs (bDMARDs) has dramatically ...
Machaon MK Bonafede,1 Jeffrey R Curtis,2 Donna McMorrow,1 Puneet Mahajan,3 Chieh-I Chen4 1Outcomes R...
Background Switching to a second tumour necrosis factor inhibitor (TNFi) after discontinuation of a ...
According to international recommendations, the selection of the biologic disease modifying anti-rhe...
Aim: To describe the persistence of biologic disease modifying anti-rheumatic drugs (bDMARDs) in Aus...
OBJECTIVE: To evaluate 4-year retention rates of tumor necrosis factor-α (TNF-α) inhibitors adalimum...
Introduction/Objective: The efficacy of biologic therapy in the treatment of rheumatoid arthritis (R...
New biologic agents have changed the paradigm of rheumatoid arthritis treatment, leading to improvem...
The aim was to describe the real-world treatment persistence of subcutaneous TNF inhibitors (TNFi) f...
Background: Rheumatoid arthritis (RA), the most common autoimmune disease in the UK, is a chronic sy...
Objective: To establish evidence-based and experts' opinion filtered statements on the optimal treat...
Objective. To evaluate 4-year retention rates of tumor necrosis factor-α (TNF-α) inhibitors adalimum...
Objective. To evaluate 4-year retention rates of tumor necrosis factor-α (TNF-α) inhibitors adalimum...